中国医药科学Issue(11)：20-22,38,4.
ERCCI和P53预测Ⅱ期结肠癌FOLFOX方案辅助化疗获益的研究
The predictive role of ERCC1 and P53 on benefit from FOLFOX adjuvant chemotherapy
摘要
Abstract
Objective To evaluate the predictive role of ERCC1 and P53 on benefit from FOLFOX adjuvant chemotherapy. Methods 58 stageⅡcolon cancer patients receiving FOLFOX adjuvant chemotherapy were included. Testing the expression level of ERCC1 and P53 by immunohistochemistry method and assessing the association of expression level with disease-free survival(DFS). Results Among 58 patients, the rate of ERCC1 expression was 62.1%, and ERCC1-negative patients had significantly longer DFS than patients with ERCC1expression (6.2 vs 5.1 years, P=0.02). However, the rate of P53 expression was 48.3%, the DFS between P53-negative and positive patients was not of statistically significant difference(5.3 vs 5.6 years, P=0.93). Conclusion In patients with stageⅡcolon cancer, ERCC1 expression may predict less benefit from FOLFOX adjuvant chemotherapy.关键词
ERCC1/P53/免疫组化/结肠癌/化疗Key words
ERCC1/P53/Immu0histochemistry/Colon cancer/Chemotherapy分类
医药卫生引用本文复制引用
彭杰文,林贵南,萧剑军..ERCCI和P53预测Ⅱ期结肠癌FOLFOX方案辅助化疗获益的研究[J].中国医药科学,2014,(11):20-22,38,4.基金项目
广东省中山市科技计划项目（20113A045）。 （）
